EP Patent

EP2275413B1 — 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Assigned to Novartis AG · Expires 2013-03-06 · 13y expired

What this patent protects

Novel pyrimidine derivatives of formula (I), to processes for their production, their use as IGF-1R and ALK-inhibitors in the treatment of neoplastic diseases, inflammatory and immune system disorders and to pharmaceutical compositions comprising them.

USPTO Abstract

Novel pyrimidine derivatives of formula (I), to processes for their production, their use as IGF-1R and ALK-inhibitors in the treatment of neoplastic diseases, inflammatory and immune system disorders and to pharmaceutical compositions comprising them.

Drugs covered by this patent

Patent Metadata

Patent number
EP2275413B1
Jurisdiction
EP
Classification
—
Expires
2013-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.